StocksExact Sciences CorpEXAS

EXAS

Exact Sciences Corp

32.49 -0.68 (-2.05%)
Delayed Prices By NASDAQ, in USD Market Closed
Trade
S
32.44
B
32.56

Overview

Prev Close32.49
Day's Range 32.41 - 34.43
52 Week Range 31.56 - 103.98
Average Volume (3m)2.15M
1-Year Return-65.12%
Beta1.3044
Market Cap5.75B
P/E Ratio
Revenue1.94B
EPS-4.229
Dividend (Yield)0 (0%)
1 Day 1 Week 1 Month 3 Months 6 Months 1 Year 3 Years Max
Created with Highcharts 4.2.7 /Highstock 4.2.720/04/202205/07/202213/09/202240.0050.0060.0070.0080.00
Chart times in UTC
Industry Biotechnology
CEO Kevin T. Conroy
Employees 6,500

FINANCIAL SUMMARY

For the fiscal year ended 31/12/2021: Exact Sciences Corp's revenues increased by 18.49% and amounted to 1.77B. Net income increased by 29.81% to -595.63M. Net assets increased by 19.98% to 3.39B and EPS increased from -5.61 to -3.48.
EXAS's Investor Relations
Income StatementBalance SheetCash Flow Statement
Quarterly
Gross Margin
68.37%
Net Profit Margin
-36.01%
Operating Margin
-35.85%
Return On Investment
-13.36%
09/21
12/21
03/22
06/22
Total Revenue
456.38M
473.81M
486.57M
521.64M
Gross Profit
316.7M
330.71M
327.21M
350.68M
Operating Income
-131.66M
-221.45M
-203.67M
-127.89M
Net Income
-166.94M
-220.61M
-180.94M
-166.06M